第三代抗癫痫新药呲仑帕奈正式在中国上市

Eisai (China) Pharmaceutical Co., Ltd. successfully held the China launch conference of Vecta® (perampanel) on December 3, 2019, marking the official launch of the new third-generation anti-epileptic drug in China. This means that China’s epilepsy treatment field has officially welcomed the first non-competitive AMPA receptor antagonist, which will bring new treatment methods and means to the majority of epilepsy patients and their families.

Perampanel is a new third-generation anti-epileptic drug that has been widely used in many countries to treat children with epilepsy since its launch. Whether it is focal epileptic seizures, generalized epileptic seizures, or some special types of epilepsy syndromes, parampanel has shown good treatment.

Perampanel is the first highly selective, non-competitive AMPA-type glutamate receptor antagonist targeting α-amino-3-hydroxy-5-methyl-4-isoranoxazole propionic acid (AMPA) receptor 2. It can selectively inhibit the increase in Ca2+ induced by AMPA and reduce the overexcitation of nerves.

There are currently some international observational studies on the effectiveness and tolerability of perampanel in the pediatric population. There is a retrospective study of 58 patients with refractory epilepsy aged 2 to 17 years old. The 50% response rate after 3 months of treatment was 31%, and 8.6% of patients had complete seizure control. The results of an Italian multicenter observational study showed that 62 pediatric patients were followed up for an average of 6.6 months, the effective rate was 50%, and the seizure-free rate was 4.8%.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.